Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Phase IIa Trial of Panacos Antiretroviral Shows Up to 90% Reduction in HIV Viral Load

August 24, 2005

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

An experimental antiretroviral drug developed by Watertown, Mass.-based Panacos Pharmaceuticals lowered participants' HIV viral loads by as much as 90% in a Phase IIa trial, the company announced on Monday, the Boston Herald reports (Arends, Boston Herald, 8/23). The drug -- called PA-457 -- is the first in a new class of antiretrovirals called maturation inhibitors, which block formation of a protein that coats HIV, according to the company. Without the coating of the protein capsid, viral copies are released from the host cell but are unable to infect other cells (AP/Yahoo! Finance, 8/22). The drug targets strains of HIV that have become resistant to other antiretroviral drugs, according to Panacos. Participants in the 10-day clinical trial were assigned to take one of four different doses of the drug once daily. The HIV-positive volunteers who took the two highest doses -- 100 milligrams and 200 milligrams -- showed significant viral load reduction (Geller, Reuters, 8/22). In addition, genetic tests conducted on 21 of the 33 participants showed no evidence of resistance to the drug (AP/Yahoo! Finance, 8/22). Panacos said it hopes to launch Phase III trials of the drug -- which is made from the bark of the European plane tree -- by early 2007 and file for market approval by 2008 (Chase, Wall Street Journal, 8/22). PA-457 has been granted fast-track status by FDA (Boston Herald, 8/23).

Back to other news for August 24, 2005

Advertisement


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More on HIV Medications
More on Maturation Inhibitors in Development

Tools
 

Advertisement